跳到正文
原文
FierceBiotech· @FierceBiotech · X·· 12 天前AI 评分47
AI 导读

MetaVia的GLP-1/胰高血糖素药物在1期试验中降低了肝脏脂肪和体重,但其竞争优势仍存疑问。该生物技术公司正转向肝病市场中竞争较少的细分方向。

正文

MetaVia's GLP-1/glucagon drug reduced liver fat and body weight in a phase 1 trial, but questions remain about its competitive edge. The biotech is now targeting a less crowded corner of the liver disease market. https://www.fiercebiotech.com/biotech/metavias-glp-1-sheds-liver-fat-and-body-weight-phase-1-fails-wow-investors

来源:FierceBiotech · x.com